Tofacitinib Inhibits Leukocyte Trafficking Across the Intestinal Endothelial Barrier in a Specific Cohort of Ulcerative Colitis Patients
Articolo
Data di Pubblicazione:
2022
Citazione:
Tofacitinib Inhibits Leukocyte Trafficking Across the Intestinal Endothelial Barrier in a Specific Cohort of Ulcerative Colitis Patients / Massimino, L.; Spano, S.; Lamparelli, L. A.; Fuggetta, D.; Peyrin-Biroulet, L.; Sileri, P.; Danese, S.; D'Alessio, S.; Ungaro, F.. - In: INFLAMMATORY BOWEL DISEASES. - ISSN 1078-0998. - 28:6(2022), pp. 971-976. [10.1093/ibd/izab349]
Abstract:
The JAK/STAT inhibitor tofacitinib, recently approved for the treatment of ulcerative colitis, is found to modulate the intestinal endothelial barrier functions in directing the leukocyte adhesion and transmigration in ulcerative colitis patients displaying high levels of endothelial STAT3/STAT6 phosphorylation.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
endothelial cells; leukocytes; transcriptomics; Ulcerative Colitis
Elenco autori:
Massimino, L.; Spano, S.; Lamparelli, L. A.; Fuggetta, D.; Peyrin-Biroulet, L.; Sileri, P.; Danese, S.; D'Alessio, S.; Ungaro, F.
Link alla scheda completa:
Pubblicato in: